BioLineRx Ltd. BLRX
1.91 USD -0.04 (-2.05%)
At closeNov 3, 2026, 4:00 PM EST
1.91 0.00 0.00%
After hours · Nov 3, 4:00 PM ET
1.90 Day range 1.99
1.90 52-week range 3.95
- YTD
- -31.05%
- 1 year
- -44.96%
- Market cap
- 9.51M
- Revenue (ttm)
- 17.05M
- Profit margin
- -176.67%
- Shares out
- 84.11M
- Forward P/E
- -1.06
- YTD return
- -31.05%
- 1-year return
- -44.96%
- Volume
- 13.37K
- Avg volume
- 17.07K
- Open
- 1.94
- Previous close
- 1.95
- Day's range
- 1.90 – 1.99
- 52-week range
- 1.90 – 3.95
- Beta
- 0.87
- Price target
- 4.57 (+139.1%)
2Y -15.29 (-88.90%)
Key statistics
- Enterprise value
- 316.99M
- PEG ratio
- 0.00
- Price / sales
- 1.34
- Price / book
- 19.45
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -15.81M
- Total cash
- 40.06M
- Total debt
- 31.25M
- Return on equity
- -171.94%
- Short % of float
- 1.33%
- 50-day average
- 0.3624
- 200-day average
- 0.62615
Analyst view
Price target (mean) 4.57 +139.1% upside
Now 1.91
- Target (low)
- 2.00
- Target (mean)
- 4.57
- Target (high)
- 9.00
Ratings (0m) 2 2 buy · 0 hold · 0 sell
- Strong buy1
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
BLRX Revenue — quarterly 294.00K
BLRX Net income — quarterly -4.34M
BLRX EPS — quarterly 0.00
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 25, 2024 | Sep 1, 2024 | -0.08 | -0.07 | +0.01 | +12.50% |
| Aug 15, 2024 | Jun 1, 2024 | -0.08 | 0.01 | +0.09 | +112.50% |
| May 28, 2024 | Mar 1, 2024 | -0.29 | -0.01 | +0.28 | +96.55% |
| Mar 26, 2024 | Dec 1, 2023 | -0.22 | -0.15 | +0.07 | +31.82% |
| Nov 20, 2023 | Sep 1, 2023 | -0.18 | -0.30 | -0.12 | -66.67% |
| Aug 30, 2023 | Jun 1, 2023 | -0.16 | -0.30 | -0.14 | -87.50% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 25, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Nov 6, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Jun 3, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| May 29, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Apr 17, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Mar 26, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About BioLineRx Ltd.
BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Israel
- Website
- biolinerx.com
News
BioLineRx And Hemispherian Present Data At ESMO 2026 Demonstrating Synergy Between GLIX1 And Multiple PARPi In Homologous Recombination-Proficient Ovarian Cancer Cell Lines And In In Vivo Patient-Derived Xenograft Model 
BioLineRx Announces That Two Abstracts Featuring GLIX1 Will Be Presented At The Society For Neuro-Oncology Annual Meeting, November 12-15 
12 Health Care Stocks Moving In Wednesday's After-Market Session 
12 Health Care Stocks Moving In Thursday's Pre-Market Session 
BioLineRx And Hemispherian To Present Preclinical Efficacy Of GLIX1 In Orthotopic Glioblastoma Models, At 21st Meeting Of EANO 2026 - 12 Health Care Stocks Moving In Wednesday's After-Market Session
BioLine Rx Q2 Sales $294.000K Miss $500.000K Estimate - 12 Health Care Stocks Moving In Friday's Pre-Market Session
BioLineRx Announces $3.75M Registered Direct Offering Of ADSs At $2.78 Each And Concurrent Private Placement Of Warrants For Up To 2M ADSs - BioLineRx To Present Pre-Clinical Data Demonstrating Strong Synergy Between GLIX1 And Various PARP Inhibitors In HR-Proficient Ovarian Cancer Cell Lines At The 2026 European Society For Medical Oncology Annual Meeting In October
Your note
Sign in to keep a note on BLRX — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Alyeska Investment Group, L.p. | 1.08% | 866,495 | 202.24K | Sep 29, 2024 |
| CVI Holdings, LLC | 1.02% | 815,683 | 190.38K | Jun 29, 2024 |
| Envestnet Asset Management | 0.30% | 239,186 | 55.83K | Sep 29, 2024 |
| Values First Advisors, Inc. | 0.25% | 197,516 | 46.10K | Sep 29, 2024 |
| Morgan Stanley | 0.25% | 197,537 | 46.10K | Sep 29, 2024 |
| Atria Investments, Inc. | 0.17% | 133,974 | 31.27K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.05% | 39,993 | 9.33K | Oct 30, 2024 |